35th ECNP CONGRESS: Welcome to the future of CNS treatments
15 – 18 October 2022, Vienna, Austria

The annual ECNP Congress is Europe’s largest meeting in applied and translational neuro-science that brings together psychiatrists, neuroscientists, neurologists, pharmacists and psychologists from around the world to discuss the latest developments in the science and treatment of brain disorders.

With about 5,000 participants, the ECNP Congress is Europe’s premier showcase for new research, treatments and technologies in applied brain science. Spanning the spectrum of human mood, behaviour, cognition and emotion, from basic science to clinical care, the ECNP Congress brings you the best in CNS innovation.

The ECNP Congress is for everyone with an interest in:
- Treatment research in psychiatry, neurology and psychology
- Mental health care
- Discoveries in neuroscience and neurobiology
- The latest developments in industry innovation
- Public policy and regulation
- Patient issues

The ECNP Congress is held at the Congress venue and presentations are given in-person by high level scientist and almost all presentations are live streamed to the online Congress platform.

Participants can choose between two participation options, in-person or online.

https://www.ecnp.eu/Congress2022/ECNPcongress
Biosimilars market in Europe, having reached the most advance stage in the process globally is still continuously gathering strength. In the recent year alone, 19 biosimilar therapeutic medicines had been granted marketing authorization, which brings over 40 EC-approved biosimilar products in the current market. Europe is bound to have another remarkable year of biosimilar approvals and launches in this coming year with EMA’s pipeline of biosimilar candidate reviews rapidly increasing.

The increasing pressure to decrease healthcare expenditures, growing demand due to its cost-effectiveness, expanding occurrence of different diseases, increasing numbers of biologics losing their market exclusivity, positive outcomes in ongoing clinical trials and rising demand in various therapeutic applications are all contributing factors for growth of the biosimilars market. Other factors increasing the demand for biosimilar drugs include rising disease incidences across the globe and better access to healthcare for all nations.

However, circumstance such as high manufacturing complexities and costs, rigorous regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict the entry of new players are restraining the growth of this market.

The 14th Biosimilars Global Congress, will cover a diverse range of topics that addresses the Strategies, Innovations and Collaborations for Sustainable Biosimilars. This will also offer and provide a unique platform for knowledge sharing and convergence from Pharmaceuticals, Biotechnology, Regulatory and many more.

More information at:

https://www.biosimilarscongress.com/